Skip to main content

Bifidobacterium animalis subsp. lactis 420 for Metabolic Health: Review of the Research

  • 2020-03-25
  • Nutrients 12(4)
    • Henna-Maria Uusitupa
    • Pia Rasinkangas
    • M. Lehtinen
    • S. Mäkelä
    • K. Airaksinen
    • H. Anglenius
    • A. Ouwehand
    • J. Maukonen

Abstract

The growing worldwide epidemic of obesity and associated metabolic health comorbidities has resulted in an urgent need for safe and efficient nutritional solutions. The research linking obesity with gut microbiota dysbiosis has led to a hypothesis that certain bacterial strains could serve as probiotics helping in weight management and metabolic health. In the search for such strains, the effect of Bifidobacterium animalis subsp. lactis 420 (B420) on gut microbiota and metabolic health, and the mechanisms of actions, has been investigated in a variety of in vitro, pre-clinical, and clinical studies. In this review, we aim to highlight the research on B420 related to obesity, metabolic health, and the microbiota. Current research supports the hypothesis that gut dysbiosis leads to an imbalance in the inflammatory processes and loss of epithelial integrity. Bacterial components, like endotoxins, that leak out of the gut can invoke low-grade, chronic, and systemic inflammation. This imbalanced state is often referred to as metabolic endotoxemia. Scientific evidence indicates that B420 can slow down many of these detrimental processes via multiple signaling pathways, as supported by mechanistic in vitro and in vivo studies. We discuss the connection of these mechanisms to clinical evidence on the effect of B420 in controlling weight gain in overweight and obese subjects. The research further indicates that B420 may improve the epithelial integrity by rebalancing a dysbiotic state induced by an obesogenic diet, for example by increasing the prevalence of lean phenotype microbes such as Akkermansia muciniphila. We further discuss, in the context of delivering the health benefits of B420: the safety and technological aspects of the strain including genomic characterization, antibiotic resistance profiling, stability in the product, and survival of the live probiotic in the intestine. In summary, we conclude that the clinical and preclinical studies on metabolic health suggest that B420 may be a potential candidate in combating obesity; however, further clinical studies are needed.

Keywords: B420; Bifidobacterium lactis; gut microbiota; metabolic health; metabolic syndrome.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactis B420Improved Epithelial IntegrityBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Reduced Weight GainBeneficial
Moderate
Bifidobacterium lactis B420Improved Epithelial IntegrityBeneficial
Moderate
Bifidobacterium lactis B420Improved Weight ManagementBeneficial
Moderate
Bifidobacterium lactis MAK16B42LImproved Epithelial IntegrityBeneficial
Moderate
Bifidobacterium lactis MAK16B42LReduced Inflammatory ProcessesBeneficial
Moderate
Bifidobacterium lactis MAK16B42LReduced Weight GainBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.